Literature DB >> 22264047

Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.

Colleen R Eade1, Matthew P Wood, Alexander M Cole.   

Abstract

Despite advances in the treatment of HIV infection, heterosexual transmission of HIV remains high, and vaccines to prevent HIV acquisition have been unfruitful. Vaginal microbicides, on the other hand, have demonstrated considerable potential for HIV prevention, and a variety of compounds have been screened for their activity and safety as anti-HIV microbicides. Among these are the naturally occurring host defense peptides, small peptides from diverse lineages with intrinsic antiviral activity. Naturally occurring host defense peptides with anti-HIV activity are promising candidates for vaginal microbicide development. Their structural variance and accompanying mechanistic diversity provide a wide range of inhibitors whose antiviral activity can be exerted at nearly every stage of the HIV lifecycle. Additionally, peptide modification has been explored as a method for improving the anti-HIV activity of host defense peptides. Structure- and sequence-based alterations have achieved varying success in improving the potency and specificity of anti-HIV peptides. Overall, peptides have been discovered or engineered to inhibit HIV with therapeutic indices of > 1000, encouraging their advancement toward clinical trials. Here we review the naturally occurring anti-HIV host defense peptides, demonstrating their breadth of mechanistic diversity, and exploring approaches to enhance and optimize their activity in order to expedite their development as safe and effective anti-HIV vaginal microbicides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264047      PMCID: PMC4270272          DOI: 10.2174/157016212799304580

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  95 in total

1.  Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity.

Authors:  H Tamamura; T Murakami; S Horiuchi; K Sugihara; A Otaka; W Takada; T Ibuka; M Waki; N Yamamoto; N Fujii
Journal:  Chem Pharm Bull (Tokyo)       Date:  1995-05       Impact factor: 1.645

Review 2.  Design, synthesis, and conformation of superpotent and prolonged acting melanotropins.

Authors:  V J Hruby; S D Sharma; K Toth; J Y Jaw; F al-Obeidi; T K Sawyer; M E Hadley
Journal:  Ann N Y Acad Sci       Date:  1993-05-31       Impact factor: 5.691

3.  Isolation and structure of novel defensive peptides from frog skin.

Authors:  A Mor; P Nicolas
Journal:  Eur J Biochem       Date:  1994-01-15

4.  Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.

Authors:  H Tamamura; M Imai; T Ishihara; M Masuda; H Funakoshi; H Oyake; T Murakami; R Arakaki; H Nakashima; A Otaka; T Ibuka; M Waki; A Matsumoto; N Yamamoto; N Fujii
Journal:  Bioorg Med Chem       Date:  1998-07       Impact factor: 3.641

5.  Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathogens.

Authors:  Fabrice Atassi; Alain L Servin
Journal:  FEMS Microbiol Lett       Date:  2009-12-24       Impact factor: 2.742

6.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

7.  A biomimetic strategy in the synthesis and fragmentation of cyclic protein.

Authors:  J P Tam; Y A Lu
Journal:  Protein Sci       Date:  1998-07       Impact factor: 6.725

8.  Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Authors:  P F Lin; H Samanta; C M Bechtold; C A Deminie; A K Patick; M Alam; K Riccardi; R E Rose; R J White; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils.

Authors:  M E Selsted; D M Brown; R J DeLange; S S Harwig; R I Lehrer
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more
  11 in total

1.  The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa.

Authors:  Colleen R Eade; Amy L Cole; Camila Diaz; Lisa C Rohan; Michael A Parniak; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole
Journal:  Am J Reprod Immunol       Date:  2012-11-20       Impact factor: 3.886

2.  A cholesterol tag at the N terminus of the relatively broad-spectrum fusion inhibitory peptide targets an earlier stage of fusion glycoprotein activation and increases the peptide's antiviral potency in vivo.

Authors:  Chuan-Gen Li; Wang Tang; Xiao-Jing Chi; Zhi-Ming Dong; Xi-Xi Wang; Xiao-Jia Wang
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  Peptide-Based Antiviral Drugs.

Authors:  N Arul Murugan; K Muruga Poopathi Raja; N T Saraswathi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.

Authors:  Aiping Wang; Fang Chen; Yingjie Wang; Mingqiang Shen; Yang Xu; Jian Hu; Song Wang; Fang Geng; Cheng Wang; Xinze Ran; Yongping Su; Tianmin Cheng; Junping Wang
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

5.  Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae.

Authors:  Lucinda Furci; Monica Tolazzi; Francesca Sironi; Lia Vassena; Paolo Lusso
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

6.  Comparative Analysis of the Integument Transcriptomes between Stick Mutant and Wild-Type Silkworms.

Authors:  Duan Tan; Hai Hu; Xiaoling Tong; Minjin Han; Songyuan Wu; Xin Ding; Fangyin Dai; Cheng Lu
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

7.  Transcripts of antibacterial peptides in chicken erythrocytes infected with Marek's disease virus.

Authors:  Sheng Niu; Ali Raza Jahejo; Fa-Jie Jia; Xin Li; Guan-Bao Ning; Ding Zhang; Hai-Li Ma; Wei-Fang Hao; Wen-Wei Gao; Yu-Jun Zhao; Shi-Min Gao; Gui-Lan Li; Jian-Hui Li; Fang Yan; Rong-Kun Gao; Yu-Hai Bi; Ling-Xia Han; George F Gao; Wen-Xia Tian
Journal:  BMC Vet Res       Date:  2018-11-21       Impact factor: 2.741

Review 8.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

9.  A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion.

Authors:  Matthew P Wood; Amy L Cole; Piotr Ruchala; Alan J Waring; Lisa C Rohan; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

Review 10.  Antiviral mechanisms of human defensins.

Authors:  Sarah S Wilson; Mayim E Wiens; Jason G Smith
Journal:  J Mol Biol       Date:  2013-10-02       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.